Industry Newsmedical devicespinal surgeryalphateccommercialization
Alphatec Reports Strong 2025 Results, 2026 Outlook
5.1
Alphatec Holdings announced preliminary 2025 results and a 2026 outlook on January 12, reporting full-year revenue up 25% to about $763.4–$764.4 million, a 26% rise in surgical revenue, and year-end cash of $161 million. The company projects $890 million revenue and roughly $130 million adjusted EBITDA for 2026, secured U.S. distribution rights for OsteoAdapt, and saw analysts reaffirm Buy ratings.
Key Points
- 1Reports revenue rising 25% to about $763.4–$764.4M, surgical revenue up 26%
- 2Secures U.S. rights for OsteoAdapt rhBMP-2, expanding surgical product portfolio and market access
- 3Projects $890M revenue and $130M adjusted EBITDA for 2026, guiding investment and planning
Scoring Rationale
Official financial update and strategic distribution deal; limited industry impact and shallow reporting reduces broader significance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
